Jacob Guggenheim is head of engineering at Vistapath. Their innovative Sentinel is bringing AI to specimen grossing.

• Jacob's background in bioengineering and robotics led him to join Vistapath

• Vistapath's mission is to improve the efficiency and accuracy of the histology process, inspired by a real-world incident

• The Sentinel is designed to augment human capabilities in grossing specimens, not replace humans

• An accomplishment Jacob is proud of is the impact of the Sentinel in providing confidence to grossing technicians through photographic evidence

• The future of Vistapath includes expanding the capabilities of the Sentinel to gross a wider range of tissue and leveraging data collected during grossing for downstream processes

• AI is already transforming pathology, but the data bottleneck is a significant barrier that needs to be addressed for further impact

Links for this episode:

Health Podcast Network

LabVine Learning

Dress A Med scrubs

Digital Pathology Club

Vistapath

First Robotics

Superlimbs

Agile Development

People of Pathology Podcast:

Twitter

Instagram

My guests today are Dr Simone Arvisais-Anhalt and Dr Daniel Qazi.

• We discussed the benefits of using LLMs in pathology, including creating outlines, data analysis, and translating reports for patients
• There are also challenges in the use LLMs, such as hallucinations and bias
• Dr. Arvisais-Anhalt and Dr. Qazi described their study on using LLMs in clinical practice
• They were some interesting findings from the study, including different use cases and limitations of the tool
• We talked about future plans to implement retrieval augmented generation for tailored responses in pathology and laboratory medicine

Links for this episode:

Health Podcast Network

LabVine Learning

Dress A Med scrubs

Digital Pathology Club

Establishing priorities for implementation of large language models in pathology and laboratory medicine

What is Retrieval Augmented Generation?

People of Pathology Podcast:

Twitter

Instagram

Jospeh Mossel co-founded Ibex in 2016. Since its inception, Ibex has remained committed to developing AI applications for clinical diagnostics.

The company achieved its first milestone in 2018 by deploying its first algorithm for prostate cancer. This algorithm not only enhanced diagnostic efficiency but also detected a diagnostic error, demonstrating the value of AI in pathology.

Over the years, IBEX has expanded its offerings to include algorithms for breast and gastric cancers, facing challenges due to the unique characteristics of each tissue type. However, through partnerships with healthcare organizations and pharmaceutical companies, IBEX has continued to innovate and grow.

This conversation covers the history of Ibex and some of their milestones. We conclude with a look toward the future of AI in pathology.

Links for this episode:

Health Podcast Network

LabVine Learning

Dress A Med scrubs

Digital Pathology Club

Ibex Medical Analytics

An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study

People of Pathology Podcast:

Twitter

Instagram